A Phase 2 interventional study of AA4500 and Placebo in Peyronie's Disease, sponsored by Endo Pharmaceuticals. Completed at 12 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing Microbial Collagenase in Penile Induration — none open to participants now, 3 under way, none of them phase 3. Microbial Collagenase · Penile Induration.
Among the 13 studies testing Microbial Collagenase in Penile Induration, this one is the 5th largest by enrollment, is the only one that started in 2008, is one of 2 in phase 2, and was the 1st registered.
48 studies on the registry are indexed under Penile Induration; 10 are open to participants now.
Browse Penile Induration studies →None of the 13 studies testing Microbial Collagenase in Penile Induration is open now. The open studies under Penile Induration, anywhere →
Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 8 Penile Induration studies recruiting now, 5 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2008.
This study's enrollment of 147 is above the median of 40 across 40 interventional studies indexed under Penile Induration.
Median enrollment 40 across the 13 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 13 have an industry lead sponsor. The 6 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
Keenova Therapeutics plc has 9 studies filed under Penile Induration — fewer than ten, so there is no comparison to draw.
2 of the studies testing Microbial Collagenase in Penile Induration that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05777031University of MiamiSafety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease | 2027-01-15 |
| NCT04786106Charitable Union for the Research and Education of Peyronie's DiseaseInvestigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's | 2027-02-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing Microbial Collagenase in Penile Induration, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated the safety and effectiveness of AA4500 in improving the impact of Peyronie's disease on quality of life and improving penile curvature in men with Peyronie's disease
A Phase 2b randomized, double-blind, placebo-controlled study of AA4500 in the treatment of subjects with Peyronie's disease.
During the screening period, subjects had a physical examination including body weight and height, vital sign measurements, a 12-lead electrocardiogram (ECG), and clinical laboratory testing. Medical history, prior and concomitant medications, and demographic data were recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clostridial collagenase for injection
Biological: AA4500
Biological: Placebo
2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.
Also known as: Clostridial collagenase for injection (AA4500)
2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.
Change From Baseline in Penile Curvature
Negative change reflects improvement in penile curvature
Time frame: Baseline and Week 36 or last observation carried forward (LOCF)
Change From Baseline in Peyronie's Disease Questionnaire (PDQ) Peyronie's Disease Symptom Bother
Peyronie's disease Symptom Bother Scale: 0-20 lower numbers reflect 'less symptom bother'; higher numbers reflect 'more symptom bother' Change from baseline equals Week 36 minus baseline. Negative change reflects improvement in the symptom bother scale.
Time frame: Baseline to Week 36 or LOCF
Change From Baseline in PDQ Intercourse Contraint
Peyronie's disease intercourse contraint Scale: 0-12 lower numbers reflect 'less intercourse contraint'; higher numbers reflect 'more intercourse constraint' Change from baseline equals Week 36 minus baseline. Negative change reflects improvement in the intercourse constraint scale.
Time frame: Baseline to Week 36 or LOCF
Change From Baseline in PDQ Intercourse Discomfort
Peyronie's disease intercourse discomfort Scale: 0-15 lower numbers reflect 'less intercourse discomfort'; higher numbers reflect 'more intercourse discomfort' Change from baseline equals Week 36 minus baseline. Negative change reflects improvement in the intercourse discomfort scale.
Time frame: Baseline to Week 36 or LOCF
Change From Baseline in PDQ Penile Pain
Peyronie's disease penile pain Scale: 0-40 lower numbers reflect 'less penile pain'; higher numbers reflect 'more penile pain' Change from baseline=Week 36 minus baseline. Negative change reflects improvement in the penile pain scale.
Time frame: Baseline to Week 36 or LOCF
| Milestone | AA4500 | Placebo |
|---|---|---|
| Started | 111 | 36 |
| Completed | 103 | 34 |
| Not completed | 8 | 2 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Protocol violation | 2 | 0 |
Negative change reflects improvement in penile curvature
| Percent change from baseline | AA4500 | Placebo |
|---|---|---|
| Change From Baseline in Penile Curvature | -29.7 ± 27.16 | -11.0 ± 30.87 |
Peyronie's disease Symptom Bother Scale: 0-20 lower numbers reflect 'less symptom bother'; higher numbers reflect 'more symptom bother' Change from baseline equals Week 36 minus baseline. Negative change reflects improvement in the symptom bother scale.
| scores on a scale | AA4500 | Placebo |
|---|---|---|
| Change From Baseline in Peyronie's Disease Questionnaire (PDQ) Peyronie's Disease Symptom Bother | -2.6 ± 4.63 | -0.8 ± 3.63 |
Peyronie's disease intercourse contraint Scale: 0-12 lower numbers reflect 'less intercourse contraint'; higher numbers reflect 'more intercourse constraint' Change from baseline equals Week 36 minus baseline. Negative change reflects improvement in the intercourse constraint scale.
| scores on a scale | AA4500 | Placebo |
|---|---|---|
| Change From Baseline in PDQ Intercourse Contraint | -1.5 ± 3.31 | -0.7 ± 3.65 |
Peyronie's disease intercourse discomfort Scale: 0-15 lower numbers reflect 'less intercourse discomfort'; higher numbers reflect 'more intercourse discomfort' Change from baseline equals Week 36 minus baseline. Negative change reflects improvement in the intercourse discomfort scale.
| scores on a scale | AA4500 | Placebo |
|---|---|---|
| Change From Baseline in PDQ Intercourse Discomfort | -0.8 ± 3.46 | -0.4 ± 4.27 |
Peyronie's disease penile pain Scale: 0-40 lower numbers reflect 'less penile pain'; higher numbers reflect 'more penile pain' Change from baseline=Week 36 minus baseline. Negative change reflects improvement in the penile pain scale.
| scores on a scale | AA4500 | Placebo |
|---|---|---|
| Change From Baseline in PDQ Penile Pain | -2.4 ± 6.32 | -0.5 ± 5.30 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AA4500 | — | 4/111 (3.6%) | 109/111 (98.2%) |
| Placebo | — | 1/36 (2.8%) | 28/36 (77.8%) |
| Event | AA4500 | Placebo |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/111 | 1/36 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/111 | 0/36 |
| Chest painGeneral disorders | 1/111 | 0/36 |
| DehydrationMetabolism and nutrition disorders | 1/111 | 0/36 |
| HypotensionVascular disorders | 1/111 | 0/36 |
| SepsisInfections and infestations | 1/111 | 0/36 |
| Neck painMusculoskeletal and connective tissue disorders | 1/111 | 0/36 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/111 | 0/36 |
| Event | AA4500 | Placebo |
|---|---|---|
| Injection site bruisingGeneral disorders | 100/111 | 18/36 |
| Injection site painGeneral disorders | 61/111 | 5/36 |
| Injection site edemaGeneral disorders | 55/111 | 0/36 |
| ContusionInjury, poisoning and procedural complications | 25/111 | 2/36 |
| Penile edemaReproductive system and breast disorders | 14/111 | 1/36 |
| Penile painReproductive system and breast disorders | 14/111 | 0/36 |
| Painful erectionReproductive system and breast disorders | 7/111 | 1/36 |
| General disorder maleReproductive system and breast disorders | 6/111 | 2/36 |
| Peyronie's diseaseReproductive system and breast disorders | 0/111 | 2/36 |
| Injection site pruritusGeneral disorders | 6/111 | 0/36 |
| Age, Categorical(Participants) | AA4500 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 95 | 34 | 129 |
| >=65 years | 16 | 2 | 18 |
| Age, Continuous(years) | AA4500 | Placebo | Total |
|---|---|---|---|
| Mean | 56.9 ± 7.79 | 55.4 ± 6.95 | 56.6 ± 7.60 |
| Sex: Female, Male(Participants) | AA4500 | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 111 | 36 | 147 |
| Region of Enrollment(participants) | AA4500 | Placebo | Total |
|---|---|---|---|
| United States | 111 | 36 | 147 |
The record gives a start of Aug 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase